![Cancer Network](https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/005/617/normal/Screenshot_2020-10-13_at_09.14.31.png?1602576896)
FDA Accepts Resubmitted BLA for Cosibelimab in Advanced Skin Cancer
Cancer Network,
Supporting data for cosibelimab in this indication came from the metastatic CSCC cohort of a phase 1 trial (NCT03212404).
Supporting data for cosibelimab in this indication came from the metastatic CSCC cohort of a phase 1 trial (NCT03212404).
The FDA received a resubmission of the biologics license application (BLA) for cosibelimab (CK-301) as a potential treatment…
WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc.
The resubmitted BLA aims to address all insufficiencies that the FDA highlighted in a complete response letter for cosibelimab…